These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2845107)

  • 1. BRL 43694: a novel antiemetic to prevent nausea and vomiting induced by chemotherapy.
    Joss RA; Richner J; Brunner KW; Rohrbach D; Pirovino M; Terrey JP; Upward J
    J Natl Cancer Inst; 1988 Oct; 80(16):1340-1. PubMed ID: 2845107
    [No Abstract]   [Full Text] [Related]  

  • 2. [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].
    Joss R; Rohrbach D; Buser K; Pirovino M; Karde C; Brunner K
    Schweiz Med Wochenschr; 1989 Jun; 119(23):831-4. PubMed ID: 2549616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Addelman M; Erlichman C; Fine S; Warr D; Murray C
    J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting.
    Falkson G; van Zyl AJ
    Cancer Chemother Pharmacol; 1989; 24(3):193-6. PubMed ID: 2544309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated use of granisetron in patients receiving cytostatic agents.
    de Wet M; Falkson G; Rapoport BL
    Cancer; 1993 Jun; 71(12):4043-9. PubMed ID: 8389659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
    Plosker GL; Goa KL
    Drugs; 1991 Nov; 42(5):805-24. PubMed ID: 1723376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiemetic efficacy of granisetron in patients receiving 5-day continuous infusion of cisplatin].
    Takahashi T; Mori K; Suga Y; Tominaga K
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1873-5. PubMed ID: 8397491
    [No Abstract]   [Full Text] [Related]  

  • 8. Caring for the cancer patient: managing emesis now. An interactive workshop. Proceedings of a satellite symposium to the 6th European Conference on Clinical Oncology. Florence, October 1991.
    Eur J Cancer; 1992; 28A Suppl 1():S1-44. PubMed ID: 1352697
    [No Abstract]   [Full Text] [Related]  

  • 9. [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs].
    Matsuishi H; Harada M; Gondo H; Otsuka T; Teshima T; Yamano Y; Omori F; Shibuya T; Yamazaki K; Taniguchi S
    Gan To Kagaku Ryoho; 1993 Aug; 20(10):1339-48. PubMed ID: 8394061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
    Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F
    J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRL 43694.
    Cancer Invest; 1989; 7(5):535. PubMed ID: 2559785
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
    Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
    Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview: oral granisetron (Kytril tablets) prophylaxis for chemotherapy-induced nausea and vomiting.
    Perez EA
    Semin Oncol; 1995 Aug; 22(4 Suppl 10):1-2. PubMed ID: 7570049
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of antiemetic therapy after the administration of high-dose antineoplastic agents.
    Trovato JA; Stull DM; Finley RS
    Am J Health Syst Pharm; 1998 Jun; 55(12):1269-74. PubMed ID: 9640466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers.
    Farley PA; Dempsey CL; Shillington AA; Kulis-Robitaille C; Colgan K; Bernstein G
    Am J Health Syst Pharm; 1997 Nov; 54(21):2478-82. PubMed ID: 9359954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient outcomes after therapeutic interchange of dolasetron for granisetron.
    Steiner MA; Yorgason RZ; Vermeulen LC; Theisen J
    Am J Health Syst Pharm; 2003 May; 60(10):1023-8. PubMed ID: 12789874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group.
    Joss RA; Dott CS
    Eur J Cancer; 1993; 29A Suppl 1():S22-9. PubMed ID: 8381293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.